利培酮联合奥氮平治疗脑器质性精神障碍疗效分析

Clinical efficacy of risperidone combined with olanzapine for the treatment of brain organic mental disorders

目的探讨利培酮联合奥氮平治疗脑器质性精神障碍的有效性和安全性,评价临床疗效。方法选择我院2011-10—2013-10收治的脑器质性精神障碍患者130例,分为对照组和观察组,对照组63例患者单独口服奥氮平治疗;观察组67例患者采用利培酮联合奥氮平治疗。2组患者均于治疗前及治疗后1、3、5、7周末使用阳性和阴性精神症状量表(PANSS)评定患者精神障碍的缓解情况,比较2组总有效率及不良反应发生率。结果观察组治疗后1周末即显示出明显效果,而对照组则在治疗后3周末才与入组时有显著性差异,且2组间PANSS量表评分及减分率在治疗后1、3、5、7周末差异均有统计学意义(P<0.01);观察组总有效率高达95.52%,显著优于对照组的85.71%,2组对比差异有统计学意义(χ2=12.13,P<0.01);2组不良反应率分别为34.33%、33.33%,差异无统计学意义(χ2=2.26,P>0.05)。结论利培酮联合奥氮平应用于治疗脑器质性精神障碍中,能显著缓解患者的精神症状,且不增加药物的不良反应,值得临床推广。

Objective To explore the efficacy and safety of risperidone combined with olanzapine for the treatment of brain organic mental disorders,and evaluated the clinical efficacy.Methods Totally 130 cases patients with brain organic mental disorders in our hospital from October 2011 to October 2013 and were divided into the control group and observation group.63 patients in the control group were treated with olanzapine;while the 67 patients in the observation group were treated with risperidone combined with olanzapine.The positive and negative syndrome scale spirit（PANSS）was used to assess the remission of mental disorders before and after treatment for 1,3,5,7weekends.The total clinical efficacy and the incidence of adverse reactions were compared.Results The observation group had significant efficacy after treatment for 1 weekend which was 3weekends in the control group.And the PANSS scores and the reduced rate between the two groups of 1,3,5,7weekends all showed a significant difference（P〈0.01）.The total clinical effective rate in the observation group was up to 95.52%,which was significantly higher than that of 85.71%in the control group,the difference was significant（χ^2=12.13,P〈0.01）;And the adverse reaction rates of the two groups were 34.33%,33.33%,which had no significant difference（χ^2=2.26,P〉0.05）.Conclusion Risperidone combined with olanzapine for the brain organic mental disorders can significantly ease the mental symptoms,and not increase the adverse drug reactions.It is worthy of clinical promotion.